Remove 2007 Remove Government Remove Manufacturing Remove Provider
article thumbnail

MN Legislative Session 2025: Updates on Health Care Bills

Minnesota Academy of Family Physicians

As we move into the tenth week of the legislative session, Minnesota Academy of Family Physicians (MAFP) lobbyist Megan Verdeja breaks down what’s happening at the Minnesota State Capitol and provides an update on health care bills. The bill passed by a voice vote and was referred to the State and Local Government Committee.

article thumbnail

Biased research, aggressive sales, harmful drugs

The Health Policy Exchange

Food and Drug Administration to market a new drug is a critical waypoint along the path to profits for pharmaceutical manufacturers. Unfortunately, recent case studies have illustrated that FDA approval does not necessarily provide assurances of effectiveness and safety. Approval from the U.S. Could the FDA and other U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Skinny Label and Induced Infringement: The Saga Continues

FDA Law Blog

government in the now-infamous (at least in FDA circles) Teva v. In the brief , the Government takes a strong position, stating “[t]he court of appeals’ holding that respondents presented sufficient evidence of petitioner’s intent to induce infringement is erroneous and warrants this Court’s review.” GSK skinny label case , the U.S.

article thumbnail

Navigating Executive Orders and DOJ Memos That Threaten Criminal Prosecution

FDA Law Blog

Specifically, these are procedures and drugs used in providing what HHS had, until recently, referred to as gender-affirming care. Department of Health & Human Services purporting to provide a comprehensive review of the evidence and best practices for promoting the health of children and adolescents with gender dysphoria.